Eli Lilly And Co vs Weibo Corp — how do they compare? Eli Lilly And Co trades at $1,220.94 (market cap $1.08T), while Weibo Corp trades at $7.75 (market cap $1.93B). The key difference: Eli Lilly And Co is far larger — about 559.6× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.
| LLY | WB | |
|---|---|---|
Market Cap | $1.08T | $1.93B |
Sector | Health | Media |
52-Week High | $1.24K | $12.83 |
52-Week Low | $639.43 | $7.20 |
Enterprise Value | $1.13T | $1.20B |
Dividend Yield | 0.57% | 7.75% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Weibo (WB) trades at $7.74, down 3.01% in the last session, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a low P/E of 5.5 and robust net income margin of 21.15%, while cash flow trends improved in 2025. Recent news highlights Q2 2026 results anticipation and AI developments, but competitive pressures persist.
The outlook is mixed; valuation metrics suggest undervaluation with analyst support, but earnings volatility and market sentiment risks require caution. Opportunities lie in cash flow strength and balance sheet health, while risks include user engagement challenges and macroeconomic headwinds in the social media sector.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →